Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Caution over inhaled insulin

Diabetes patients should only be offered inhaled insulin if they are so opposed to the idea of injections that they will otherwise delay treatment, researchers have concluded.

Their meta-analysis found inhaled insulin was slightly less effective than the injectable form at achieving glycaemic control, although it did increase patient acceptability.

Patients with type 1 or type 2 diabetes using inhaled insulin had levels of HbA1c an average of 0.08 points higher than those on subcutaneous insulin.

Study leader Dr Lisa Ceglia, a researcher in the division of endocrinology, diabetes and metabolism at Tufts-New England Medical Center in Boston, said: 'Until long-term safety data is available, inhaled insulin should be reserved for non-pregnant adults with diabetes who are opposed to injections and who would otherwise delay appropriate and timely therapy.'

The conclusions are more cautious than the NICE provisional appraisal on inhaled insulin, which proposes merely restricting its use to patients with needle-phobia.

Dr Martin Hadley Brown, chair of the Primary Care

Diabetes Society and a GP in Norfolk, said: 'We have a responsibility to use the drug budget effectively, and I don't think

inhaled insulin stacks up.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say